APT Medical (688617) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 reached RMB 1,000.96 million, up 27.03% year-over-year, with net profit attributable to shareholders at RMB 342.56 million, up 33.09% year-over-year.

• Gross margin and profitability improved due to sales growth, cost control, and efficiency gains.

• R&D investment remained high, supporting product innovation and pipeline expansion.

• Domestic and international market coverage expanded, with significant growth in both hospital coverage and overseas sales.

Financial highlights

• Operating income: RMB 1,000.96 million, up 27.03% year-over-year.

• Net profit attributable to shareholders: RMB 342.56 million, up 33.09% year-over-year.

• Operating profit: RMB 389.78 million, up 33.39% year-over-year.

• Basic EPS: RMB 5.12, up 32.64% year-over-year.

• Cash flow from operations: RMB 343.48 million, up 3.67% year-over-year.

• R&D expenses: RMB 133.89 million, up 22.92% year-over-year.

Outlook and guidance

• Continued focus on R&D and product innovation to maintain competitive edge.

• Plans to accelerate new product launches and expand international presence.

• Management expects ongoing growth in both domestic and overseas markets, supported by policy tailwinds and aging demographics.